63results about How to "Realize individualized treatment" patented technology

The invention provides a method and a kit for detecting BRCA1 and BRCA2 gene mutation. The method and the kit utilize two sets of PCR (polymerase chain reaction) primers, wherein a first set of PCR primers comprises 189 pairs of PCR primers and is divided into two groups, a first group comprises 95 pairs of primers with sequences represented as SEQ ID NO.5-SEQ ID NO.194, a second group comprises 94 pairs of primers with sequences represented as SEQ ID NO.195-SEQ ID NO.382, a sequence represented as SEQ ID NO.1 is added to the 5' end of each upstream primer, and a sequence represented as SEQ ID NO.2 is added to the 5' end of each downstream primer; sequences of upstream and downstream primers of a second set of PCR primers are represented as SEQ ID NO.3 and SEQ ID NO.4.

The invention relates to application of DNA (Deoxyribonucleic Acid)-PKcs in preparation of a medicine for influencing dihydrofolate reductase (DHFR) gene amplification and changing the drug resistance of tumor cells on MTX (Methotrexate) and belongs to biological medicines. The application comprises the following steps: establishing an MTX drug-resistant cell evolution model, selecting low-concentration drug-resistant (HSRs) and high-concentration drug-resistant (DMs) cells as research objects, detecting the gene amplification degree and form in the parent cells and drug-resistant cells, the DNA damage conditions and DNA-PKcs expression conditions, establishing clone which stably interferes the DNA-PKcs in the MTX drug-resistant cells aiming at the core protein DNA-PKcs in the NHEJ path, and detecting the amplification degree and form of DHFR genes in stable interference clone, the cell growth and apoptosis and change of the drug resistance.

The invention discloses a tumor-targeted delivery carrier based on cell-derived micro-vacuoles, a preparation method and an application. The preparation method comprises the following steps of: (A) preparing a conditioned medium: supplementing fetal bovine serum, antibiotics, DSPE-PEG-Biotin and DSPE-PEG-Folate into a basal medium; (B) using the obtained conditioned medium in cell culture, and collecting cell culture supernatant for subsequent separation; (C) carrying out low-speed centrifugation on the obtained culture supernatant to remove cell debris and apoptotic bodies, then adding SA-IONPs, mixing uniformly, incubating, then separating by a magnet, using PBS for re-suspension, eluting for multiple times to obtain the cell-derived micro-vacuoles with membrane surfaces modified by folic acid and iron oxide nano-particles, and freezing for storage; and (D) loading chemotherapeutic drugs or therapeutic genes into the functionalized micro-vacuoles doubly-modified by an electroporation mode, and carrying out re-suspension after separation with the magnet. The tumor-targeted delivery carrier based on cell-derived micro-vacuoles, the preparation method and the application disclosed by the invention are applicable to specific targeting delivery of multiple chemotherapeutic drugs and therapeutic genes, and have the advantages of enhancing the anti-tumor effect, reducing the systemic toxicity and improving the clinical effect of the current therapeutic selection, so that a new hope is brought for clinical therapy of tumors.

The invention belongs to the field of biomedical engineering, and relates to a human tissue-engineered cardiac muscle tissue and a preparation method thereof. The human tissue-engineered cardiac muscle tissue disclosed by the invention is prepared by inoculating all kinds of cell components of a normal heart differentiated from human induced multipotential stem cells by taking a natural decellularized heart substrate as the scaffold. The human tissue-engineered cardiac muscle tissue has cell components, extracellular matrixes and biological functions similar to that of a normal human cardiac muscle tissue; testing and screening of in-vitro drugs, initial in-vivo transplantation researches of clinical earlier-stage small animals and observation of treatment effects can be carried out; and helps can be finally offered for realizing individualized treatment of human cardiovascular diseases.

The invention relates to the biomedicine field, and specifically relates to a method for screening potential biomarkers of gastric cancer based on weighted gene co-expression network analysis, and application thereof. The method for screening potential biomarkers of gastric cancer adopts weighted gene co-expression network analysis (WGCNA) and KEGG pathway and GO enrichment analysis, and other analysis methods. Weighted Gene Co-Expression Network Analysis (WGCNA) is an efficient and comprehensive method for high-dimensional data analysis, and the accuracy and validity in analyzing gene chip data of the WGCNA has been confirmed. The potential biomarker screened by the method of the invention is FERMT2. The method for screening potential biomarkers of gastric cancer based on weighted gene co-expression network analysis provides a new direction for the diagnosis, treatment and prognosis of gastric cancer, and promotes the development of individualized treatment.

The invention belongs to the fields of genetic engineering and oncology, and discloses an SNP marker related to liver toxicity of platinum type chemotherapeutic medicines and applications thereof. The marker is a composition of rs6681909, rs4140932, rs13131227, rs4446279, rs17053350, rs9402873, rs16878272, rs13267737, rs7008590, rs947853, rs2838566, rs1383888, rs9642723, rs3822296, rs2160046, rs10002931, rs10032941, rs6449138, rs1048037 and rs10086636. The marker and primer probes thereof can be used for preparing a diagnosis kit of the liver toxicity of platinum type chemotherapeutic medicines, and are good in sensitivity and specificity.

The invention discloses application of lncRNA combination to preparation of a product for predicting renal clear cell carcinoma prognosis and molecular targeted medicine treatment sensitivity. The lncRNA or the lncRNA combination serving as a detection target point is applied to preparation of the product for predicting renal clear cell carcinoma prognosis and molecular targeted medicine treatmentsensitivity, and the lncRNA or the lncRNA combination is selected from any one or more of SEQ ID NO.1 to SEQ ID NO.4. A new clinical method is provided for evaluating prognosis of patients sufferingfrom renal clear cell carcinoma, new reference advice is provided for auxiliary treatment after operation of the renal clear cell carcinoma, and important clinical significance and popularization andapplication prospect in the aspects of timely taking effective clinical measures, formulating an individualized diagnosis and treatment scheme and finally increasing the survival rate of the patientssuffering from the renal clear cell carcinoma are achieved.

The invention relates to the technical field of a machine, in particular to a hand-foot rehabilitation therapeutic instrument, which comprises a wrist sleeve and a palm sleeve disposed at one end of the wrist sleeve, wherein the other end of the palm sleeve is provided with a plurality of finger sleeves. The hand-foot rehabilitation therapeutic instrument is in contact with the finger joint of thefingers through an eccentric wheel of a micromotor to perform activities on the knuckles of a patient, promotes the recovery of the extremity of the limb, reduces disability, and reduces the burden on the family and society. A fingertip massage method is the same as the reverse playing of a piano, a finger rest corresponding to a note is ejected to facilitate the massage of the patient's finger,an AH173 Hall sensor can count the number of grip strengths so as to facilitate feedback on the treatment situation in time, and by setting a wireless control device, the operation of the product canbe continuously carried out to complete the rehabilitation treatment in the event that the patient has speech ambiguity.

The invention discloses a heart and brain dual targeting lipidosome as well as a preparation method and applications of the heart and brain dual targeting lipidosome. The heart and brain dual targeting lipidosome is obtained by coupling an Anti-cTnI protein antibody or a fragment of the Anti-cTnI protein antibody on the surface of a lipidosome modified by an acetylated glycoester-polyethylene glycol-phosphatidyl ethanolamine conjugate as shown in the formula I. According to the technical scheme, by modifying the mannose molecule derivative and the Anti-cTnI protein antibody on the surface of the lipidosome, the lipidosome has the dual targeting effects including brain targeting and heart targeting, and the treatment for the heart and the brain can be realized. The in-vitro cell experiment,the affinity experiment and the in-vivo distribution experiment prove that the lipidosome can treat myocardial diseases, and also can span the blood brain barrier for treating diseases caused by cardiogenic diseases. In addition, by changing the length of the PEG (Linker) on the surface of the lipidosome, the spatial positions of the sugar molecule derivative and the antibody can be changed, thusthe distribution of medicines in the heart and the brain tissue can be changed, the distribution change of the medicines in the heart and the brain can be regulated, and the individualized treatmentis realized.

The invention relates to a refined and scientific diagnosis and treatment system. The system comprises patient terminals, department terminals in hospitals and a central processor, wherein the central processor serves as a transfer connecting the patient terminals with the department terminals, and is also connected to the national identity information system; the patient terminals are provided with photographing and scanning structures and fingerprint recognition structures; all information about the departments in the hospitals and disease diagnosis and treatment conditions is stored in the central processor; the patient terminals are also provided with orientation systems while the central processor is provided with a position analysis system; the patient terminals are internally provided with payment modules while the central processor is internally provided with a fund reception module; in addition, the central processor is also connected to the medical insurance system, and the patient terminals are internally provided with medical insurance card-bonding structures, so a person can directly see a doctor and pay with a medical insurance card. Through the refined and scientific diagnosis and treatment system, the hospitals and the departments of the hospitals can be connected, thereby enabling patients to see a doctor in a nearby hospital and pay online.

The invention discloses an SNP marker composition related to onset risk of brain radiation injury caused by tumor radiotherapy and application thereof. The SNP marker composition comprises 15 SNP loci. Meanwhile, a kit for predicating the onset risk of brain radiation injury caused by tumor radiotherapy is prepared, the kit is adopted to detect types of SNP markers, and the onset risk of onset risk of patients suffering from nasopharyngeal carcinoma can be more comprehensively and accurately detected estimated through clinic information of the patients. Through the adoption of the SNP marker composition to clinical applications, and adoption of protective measures in advance to high-risk patients, the SNP marker composition is beneficial to implementation of individualized treatment to thepatients, and improves the long-term survival quality of the patients suffering from nasopharyngeal carcinoma. Meanwhile, the SNP marker composition can provide a method and tactical reference for the predication of risk of normal tissue injury caused by other radiotherapies.

The invention belongs to the field of biomedicines and relates to an Lnc RNA model for prediction of poor prognosis risk of pancreatic cancer patients and a detection kit. The model includes four parts: sample collection, RNA extraction, Lnc RNA measurement, and Lnc RNA expression quantity weighting calculation. The Lnc RNA includes seventeen Lnc RNAs which are obtained through screening and are related to prognosis of the pancreatic cancer. In the invention, by detecting the expression level of the Lnc RNA of patients, the model can be applied to clinical determination on prognosis of the pancreatic cancer patients; the seventeen Lnc RNAs can be used as markers for predicting postoperative survival of pancreatic cancer patients. The invention also provides the corresponding kit, by whichthe level of the Lnc RNA of the postoperative pancreatic cancer patients can be detected in order to determine the prognosis of the pancreatic cancer patients. The model and the kit are high in throughput and sensitivity.

The invention relates to a kit for predicting the curative effect of glucocorticoids on curing SLE (Systemic Lupus Erythematosus) on basis of an HSP90AB1 genotype. The kit comprises the components: a primer for detecting the HSP90AB1 gene polymorphism site genotype, a PCR (Polymerase Chain Reaction) amplification enzyme and a corresponding buffer solution, a PCR product purification enzyme, dNTP (Diethyl-nitrophenyl Thiophosphate), a single-base extension reaction enzyme and a corresponding buffer solution, and a single-base extension product purification enzyme. When the HSP90AB1 gene rs9367190 polymorphism site genotype is CA and/or AA, the curative effect of the glucocorticoids on curing the SLE (Systemic Lupus Erythematosus) is predicted to be good. When a haplotype formed by rs9367190 and rs13296 polymorphism sites is CA, the curative effect of the glucocorticoids on curing the SLE is predicted to be poor. When an rs13296 polymorphism site genotype is GA and/or AA, the living quality (the mental health) improvement of an SLE patient cured by the glucocorticoids is predicted to be poor. The invention provides a new idea and a new method for guiding individualized treatment of SLE patients.

The invention relates to the technical field of medical devices, in particular to an intelligent angle-measurement multifunctional auxiliary treatment chair for cervical spondylosis, and aims to solve problems that with acceleration of pace of life, long-term overtime working, driving and the like of young people are increasingly common and patients with cervical spondylosis are continuously increased. Front flexion and rear extension, left and right rotation, and left and right lateral flexion and traction are independently controlled by stepping motors for independent movement and sequential and circular movement, and program control is facilitated; Height of a chair seat and a head fixing device can be freely adjusted, and individualized treatment can be achieved for patients with different illness conditions; the patients can freely change body positions between 90 degrees (sitting posture) and 180 degrees (lying posture), movement angles and traction forces have program and mechanical dual protection functions, and neck movement angles and the traction forces are strictly controlled within an allowable range; and a wireless device is used to meet operation requirements of the patients at different treatment body positions, such that the intelligent angle-measurement multifunctional auxiliary treatment chair can realize self-service treatment, and is suitable for hospital treatment and family treatment.

The invention discloses a 3D printed vaginal drug delivery device. The device is prepared through 3D printing, and polymer, medicine, pore former and surface active agent are included. The shape of the device can be selected from an O-shape, a Y-shape, an M shape, a T shape, a V shape, a U shape, a twisted shape, a triangle shape, an anchor shape, and other special shapes designed according to disease demands and personal characteristics. The device is characterized in that an individualized design is adopted, medicine carrying dosage can be adjusted, using is convenient, and the shape and themedicine carrying dosage can be flexibly changed according to the personal characteristics and demands to achieve personalized treatment.

The present invention discloses an application, of an SNP site rs10501719 on a DISC1FP1 gene, as a marker associated with the risk of radiation induced brain injuries caused by tumor radiotherapy. A kit for predicting the risk of radiation induced brain injuries caused by tumor radiotherapy is prepared. The kit can be used to detect SNP marker typing, and clinical information of patients can be combined to more comprehensively and accurately assess the risk of occurrence of radiation induced brain injuries in patients with nasopharyngeal carcinoma. The kit is applied to clinical practice, andprotective measures are taken in advance for high-risk patients, thus facilitating individualized treatment of patients and improving long-term quality of life of patients with nasopharyngeal carcinoma. In addition, a methodological and strategic reference for risk prediction of normal tissue injuries caused by other radiotherapy can be provided.

The invention discloses an application of ARRDC2 in evaluating the development process of oral squamous cell carcinoma. According to the invention, by means of high throughput sequencing and bioinformatics analysis, gene ARRDC2, which indicates significant changes in different development processes of the tumor, is screened, and ARRDC2 is suggested, as a marker molecule, to be applied to determination of the development of the oral squamous cell carcinoma, prediction of the prognosis of the tumor and guiding of therapeutic plans and curative effect monitoring.

The invention discloses a target gene for diagnosis of oral squamous cell carcinoma and application thereof. By screening genes with an expression level related to a tumor differentiation level, the expression of genes in tumor tissues in each differentiation level is determined, so that the differentiation level of a tumor is determined, thereby accurately and objectively predicting the tumor prognosis, guiding the formulation of a treatment plan and monitoring a therapeutic effect.